Replimune Group (NASDAQ:REPL) Announces Earnings Results

Replimune Group (NASDAQ:REPL) announced its earnings results on Wednesday. The company reported ($0.79) EPS for the quarter, missing the consensus estimate of ($0.70) by ($0.09), Zacks reports.

Replimune Group Stock Down 1.7 %

Shares of NASDAQ REPL traded down $0.23 during mid-day trading on Thursday, reaching $13.56. The company had a trading volume of 44,777 shares, compared to its average volume of 761,002. The company has a debt-to-equity ratio of 0.18, a quick ratio of 10.11 and a current ratio of 10.11. Replimune Group has a twelve month low of $4.92 and a twelve month high of $17.00. The stock’s 50 day moving average is $12.49 and its 200-day moving average is $11.67. The stock has a market capitalization of $927.50 million, a PE ratio of -4.46 and a beta of 1.30.

Analyst Ratings Changes

A number of equities analysts recently commented on REPL shares. HC Wainwright raised their price objective on shares of Replimune Group from $21.00 to $22.00 and gave the stock a “buy” rating in a research note on Thursday. BMO Capital Markets raised their target price on Replimune Group from $18.00 to $27.00 and gave the stock an “outperform” rating in a research report on Wednesday, January 22nd. Finally, Jefferies Financial Group upped their price target on Replimune Group from $16.00 to $19.00 and gave the company a “buy” rating in a research report on Wednesday, December 4th. Seven equities research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat, the stock has an average rating of “Buy” and a consensus price target of $19.29.

Insider Activity at Replimune Group

In other news, CEO Sushil Patel sold 10,000 shares of the firm’s stock in a transaction on Monday, December 16th. The shares were sold at an average price of $12.42, for a total transaction of $124,200.00. Following the transaction, the chief executive officer now owns 202,014 shares in the company, valued at approximately $2,509,013.88. This trade represents a 4.72 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, insider Konstantinos Xynos sold 7,246 shares of the company’s stock in a transaction on Monday, November 18th. The stock was sold at an average price of $10.78, for a total transaction of $78,111.88. Following the completion of the sale, the insider now owns 109,885 shares of the company’s stock, valued at $1,184,560.30. This represents a 6.19 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders own 8.80% of the company’s stock.

About Replimune Group

Replimune Group, Inc, a clinical-stage biotechnology company, focuses on the development of oncolytic immunotherapies to treat cancer. The company's proprietary tumor-directed oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF, which is in Phase I/II clinical trials for a range of solid tumors; and that has completed Phase II clinical trials for treating cutaneous squamous cell carcinoma.